IGKV2D-24 and Alzheimer disease: Considering that α7 and α4β2 subtypes of nAChRs are involved in AD pathogenesis [13], the use of nAChRs modulators to increase the availability for ACh and to overcome the death of the forebrain cholinergic neurons represent a new therapeutic strategy for AD [14].